Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada

Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.

Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.

Disclosures

Dr. Lin has consulted with the following companies on Continuing Medical Education programs:

Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.

No clinical trials. No patents.

Recent Contributions to PracticeUpdate:

  1. Sulfonylureas as Second-Line Drugs for Cardiovascular Safety in Type 2 Diabetes
  2. Association of Sulfonylureas With the Risk of Dementia
  3. Primary Occurrence of Cardiovascular Events in Veterans With Diabetes After Adding SGLT2 Inhibitors or GLP-1 Receptor Agonists Compared With DPP-4 Inhibitors
  4. Association of Hypertriglyceridemia With Renal Function Decline and the Development of End-Stage Kidney Disease in a Real-World Clinical Setting
  5. Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension
  6. Aspirin vs Clopidogrel for Long-Term Maintenance After Coronary Stenting in Patients With Diabetes
  7. Subclinical Coronary Atherosclerosis and the Risk for Myocardial Infarction
  8. Separate and Combined Effects of Semaglutide and Empagliflozin on Kidney Oxygenation and Perfusion in People With Type 2 Diabetes
  9. Changes in Cardiorespiratory Fitness and Survival in Patients With or Without CVD
  10. Inflammation Contributes to Cardiovascular Risk in Patients Receiving Statin Therapy

Most Read This Week

Recently Updated